Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 22 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 19 20 21 22 presentations: 1 to 25 of 543
Immuno-oncology Clinical Trials I
Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Michael Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Padmanee Sharma
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Matteo Carlino
Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Wentworthville, Australia
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Charles G. Drake
Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Yong-Chen Lu
National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Precision Medicine Early Clinical Trials
Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 "CREATE"
Patrick Schoffski
University Hospitals Leuven - Department of General Medical Oncology, Leuven, Belgium
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Ravi Salgia
City of Hope, Duarte, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
Alexander Drilon
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
David S Hong
MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Leena Gandhi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Transformative Clinical Trials in Breast Cancer
Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes
Martine Piccart
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Discussant
Harold J Burstein
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial
Monica Arnedos
Institut Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Discussant
Nancy E. Davidson
University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Angela M DeMichele
University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Discussant
Mark D Pegram
UCLA School of Medicine, Los Angeles, CA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Low-fat dietary pattern and breast cancer mortality in the Women's Health Initiative (WHI) randomized trial
Rowan T Chlebowski
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Chairperson
Elizabeth M. Jaffee
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer
Leisha A Emens
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Issues faced by industry in developing safe and effective combination immunotherapies
Ira Mellman
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Statistical challenges in designing combination immunotherapy clinical trials
Katy Simonsen
Bristol-Myers Squibb Co., Princeton, NJ, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
<< first | < prev page: of 22 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 19 20 21 22 presentations: 1 to 25 of 543